Heterogeneous Epstein–Barr virus latent gene expression in AIDS-associated lymphomas and in type I Burkitt's lymphoma cell lines

References

1. Barletta J. M., Kingma D. W., Ling Y., Charache P., Mann R. B., Ambinder R. F. 1993; Rapid in situ hybridization for the diagnosis of latent Epstein–Barr virus infection. Mol Cell Probes 7:105–109
   [Google Scholar]
2. Bodescot M., Perricaudet M. 1986; Epstein–Barr virus mRNAs produced by alternative splicing. Nucleic Acids Res 14:7103–7114
   [Google Scholar]
3. Diebold J., Jaffe E. S., Raphaël M., Warnke R. A. 2001; Burkitt’s lymphoma in pathology and genetics. In Tumours of Haematopoietic and Lymphoid Tissue pp  181–184 Edited by Jaffe E. S., Harris N. L., Stein H., Vardiman J. W. Lyon: IARC;
   [Google Scholar]
4. Fahmi H., Cochet C., Hmama Z., Opolon P., Joab I. 2000; Transforming growth factor β 1 stimulates expression of the Epstein–Barr virus BZLF1 immediate-early gene product ZEBRA by an indirect mechanism which requires the MAPK kinase pathway. J Virol 74:5810–5818
   [Google Scholar]
5. Gaidano G., Capello D., Carbone A. 2000; The molecular basis of acquired immunodeficiency syndrome-related lymphomagenesis. Semin Oncol 27:431–441
   [Google Scholar]
6. Hamilton-Dutoit S. J., Raphaël M., Audouin J., Diebold J., Lisse I., Pedersen C., Oksenhendler E., Marelle L., Pallesen G. 1993; In situ demonstration of Epstein–Barr virus small RNAs (EBER-1) in acquired immunodeficiency syndrome-related lymphomas: correlation with tumor morphology and primary site. Blood 82:619–624
   [Google Scholar]
7. Harris N. L., Jaffe E. S., Stein H. 7 other authors 1994; A revised European–American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 84:1361–1392
   [Google Scholar]
8. Hudson G. S., Farrell P. J., Barrell B. G. 1985; Two related but differentially expressed potential membrane proteins encoded by the Eco RI Dhet region of Epstein–Barr virus B95-8. J Virol 53:528–535
   [Google Scholar]
9. Kelly G., Bell A., Rickinson A. 2002; Epstein–Barr virus-associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2. Nat Med 8:1098–1104
   [Google Scholar]
10. Kerdiles B., Walls D., Triki H., Perricaudet M., Joab I. 1990; cDNA cloning and transient expression of the Epstein–Barr virus-determined nuclear antigen EBNA3B in human cells and identification of novel transcripts from its coding region. J Virol 64:1812–1816
    [Google Scholar]
11. Kieff E., Rickinson A. B. 2001; Epstein–Barr virus and its replication. In Fields Virology , 4th edn. pp  2511–2573 Edited by Fields B. N., Howley P.M. Philadelphia: Lippincott Williams & Wilkins;
    [Google Scholar]
12. Lear A. L., Rowe M., Kurilla M. G., Lee S., Henderson S., Kieff E., Rickinson A. B. 1992; The Epstein–Barr virus (EBV) nuclear antigen 1 Bam HI F promoter is activated on entry of EBV-transformed B cells into the lytic cycle. J Virol 66:7461–748
    [Google Scholar]
13. Martel-Renoir D., Grunewald V., Touitou R., Schwaab G., Joab I. 1995; Qualitative analysis of the expression of Epstein–Barr virus lytic genes in nasopharyngeal carcinoma biopsies. J Gen Virol 76:1401–1408
    [Google Scholar]
14. Niedobitek G., Agathanggelou A., Rowe M., Jones E. L., Jones D. B., Turyaguma P., Oryema J., Wright D. H., Young L. S. 1995; Heterogeneous expression of Epstein–Barr virus latent proteins in endemic Burkitt's lymphoma. Blood 86:659–665
    [Google Scholar]
15. Nonkwelo C., Skinner J., Bell A., Rickinson A., Sample J. 1996; Transcription start sites downstream of the Epstein–Barr virus (EBV) Fp promoter in early-passage Burkitt lymphoma cells define a fourth promoter for expression of the EBV EBNA-1 protein. J Virol 70:623–627
    [Google Scholar]
16. Radkov S. A., Bain M., Farrell P., West M., Rowe M., Allday M. 1997; Epstein–Barr virus EBNA3C represses Cp, the major promoter for EBNA expression, but has no effect on the promoter of the cell gene CD21. J Virol 71:8552–8562
    [Google Scholar]
17. Raphaël M., Borisch B., Jaffe E. S. 2001; Lymphomas associated with infection by the human immunodeficiency virus (HIV). In Tumours of Haematopoietic and Lymphoid Tissues pp  260–263 Edited by Jaffee E. S., Harris N. L., Stein H., Vardiman J. W. Lyon: IARC;
    [Google Scholar]
18. Rowe M., Young L. S., Cadwallader K., Petti L., Kieff E., Rickinson A. B. 1989; Distinction between Epstein–Barr virus type A (EBNA 2A) and type B (EBNA 2B) isolates extends to the EBNA 3 family of nuclear proteins. J Virol 63:1031–1039
    [Google Scholar]
19. Rickinson A. B., Moss D. J. 1997; Human cytotoxic T lymphocyte responses to Epstein–Barr virus infection. Annu Rev Immunol 15:405–431
    [Google Scholar]
20. Sample J., Brooks L., Sample C., Young L., Rowe M., Gregory C., Rickinson A. B., Kieff E. 1991; Restricted Epstein–Barr virus protein expression in Burkitt lymphoma is due to a different Epstein–Barr nuclear antigen 1 transcriptional initiation site. Proc Natl Acad Sci U S A 88:6343–6347
    [Google Scholar]
21. Speck S. H., Strominger J. L. 1985; Analysis of the transcript encoding the latent Epstein–Barr virus nuclear antigen I: a potentially polycistronic message generated by long-range splicing of several exons. Proc Natl Acad Sci U S A 82:8305–8309
    [Google Scholar]
22. Tierney R. J., Steven N., Young L. S., Rickinson A. B. 1994; Epstein–Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state. J Virol 68:7374–7385
    [Google Scholar]